Active in the arenas of mRNA therapeutics and synthetic biology, Strand Therapeutics is an emerging biopharmaceutical company applying synthetic biology to RNA therapeutics and developing the first platform for the creation of programmable, long-acting mRNA drugs capable of delivering precise, multi-functional, potentially curative treatments with a single dose. Co-founded by leading mRNA researchers from the MIT Synthetic Biology Center, Strands technology potentially has broad applicability across a spectrum of diseases. Initially, the firm is focused on development of mRNA therapies that act through multiple immune mediated mechanisms to deliver potentially curative treatments in oncology. In the solid tumors space, Strands mRNA approach has the potential significantly to improve response rates to checkpoint inhibitor therapy. Where hematological tumors are the focus, Strands early work may have the potential to revolutionize CAR-T therapy. A relative newcome to the SBIR arena but hit the gound runnubg wth three NIH awards ver soon after founding
